Brandon Capital
VC Fund
Melbourne, Australia
Brandon Capital is a VC fund in Melbourne focused on Biotechnology and Health Care. Brandon Capital Partners is a funds management business aiming to generate quality returns for Australia's leading superannuation funds by investing in innovative life science ventures. Our team works with entrepreneurs to build businesses, creating value for the entrepreneurs, their teams and our investors.
- Total investments:
- 80
- Last investment:
- Lead investor:
- 33%
- Fund size:
- $210M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Brandon Capital invests in
Stages Brandon Capital invests in
Countries Brandon Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $673k–$9.7M
- Series A
- $5.2M–$81M
- Series B
- $6.4M–$68M
Investment Focus
Industry
- Biotechnology 35 (44%)
- Health Care 27 (34%)
- Medical 20 (25%)
- Therapeutics 15 (19%)
- Pharmaceutical 13 (16%)
Stage
- Series A 21 (26%)
- Seed 12 (15%)
- Series B 11 (14%)
- Funding Round 7 (9%)
- Venture - Series Unknown 7 (9%)
Country
- Australia 29 (36%)
- United Kingdom 8 (10%)
- United States 6 (8%)
- New Zealand 2 (3%)
- Israel 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chris Nave
Partner, Managing Director & Co-Founder
|
Partner, Managing Director & Co-Founder | Total investments: 18 | Find email | |
Robert Daniels
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Stephen Thompson
Partner
|
Partner | Total investments: 8 | Find email | |
Bob Soh
Senior Investment Manager
|
Senior Investment Manager | Total investments: 2 | Find email | |
Darren Kelly
Entrepreneur in Residence
|
Entrepreneur in Residence | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
OncoRes Medical
|
OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to assist with the identification of tumor and healthy tissue.OncoRes Medical is an early-stage medical device company located in Perth, Western Australia and is developing the patent-protected technology in collaboration with leadingresearchers at the University of Western Australia and the Harry Perkins Institute of Medical Research and breast cancer surgeons at the Western Australian public health system.With funding provided by the Medical Research Commercialisation Fund (MRCF), OncoRes Medical aims to develop the technology for use in clinical applications that require the real-time assessment of tissue microstructure. | $19.2M / Venture - Series Unknown / Feb 12, 2026 | |
Lumonus
|
Lumonous is a healthcare company that offers Radiation Oncology, Radiation Therapy, and Cancer treatment technology-enabled services. | $18.2M / Series B / Nov 06, 2025 | |
Ena Respiratory
|
Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $22.4M / Series B / Oct 22, 2025 | |
|
Ena Respiratory
|
Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs. | $22.4M / Series B / Oct 22, 2025 | |
NRG Therapeutics
|
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $67.8M / Series B / Sep 08, 2025 | |
Vaxxas
|
Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. | $31.8M / Series D / Aug 25, 2025 | |
Mirugen
|
Mirugen is a preclinical biotechnology company identifying the optimal set of cellular instructions to ask one cell type to become another. | $2.9M / Seed / Aug 13, 2025 | |
Allay Therapeutics
|
Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | $57.5M / Series D / Jun 05, 2025 | |
PolyActiva
|
PolyActiva has developed proprietary drug-polymer conjugate technology that enables site-specific drug delivery from medical device components such as ocular implants, intra-articular gel implants, and drug-eluting fibers. | $25.7M / Series C / May 30, 2025 | |
AdvanCell
|
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $112M / Series C / Feb 03, 2025 | |
| See all 80 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Brandon Capital invest in?
Brandon Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 80 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Brandon Capital's check size?
Brandon Capital typically joins rounds of $673k–$9.7M at Seed, $5.2M–$81M at Series A and $6.4M–$68M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Brandon Capital participates in.
How do I contact Brandon Capital?
Public channels for Brandon Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Brandon Capital?
The team at Brandon Capital includes Chris Nave (Partner, Managing Director & Co-Founder), Robert Daniels (Venture Partner) and Stephen Thompson (Partner), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
